At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 106 enrolled
Drug / intervention
Dasatinibdrug
Likely dose
Dasatinib 60 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multi-Center, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
In Brief
A Phase 2 clinical trial evaluating Dasatinib for Leukemia, Pediatric. Completed, enrolled 106 participants across 128 sites in 6 countries.
Detailed Summary
The purpose of this study is to determine whether Dasatinib when added to standard chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome positive acute lymphoblastic leukemia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Pediatric
CountriesAustralia, Canada, Italy, Puerto Rico, United Kingdom, United States
CollaboratorsChildren's Oncology Group, EsPhALL
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 2011
Enrollment StartApr 2012
Primary CompletionMay 2017
Study CompletionJun 2021
TodayJul 2026
First PostedOct 26, 2011
Enrollment StartApr 13, 2012
Primary CompletionMay 28, 2017
Study CompletionJun 1, 2021
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 14.7 years ago
Interventions
Dasatinibdrug
Tablets, Oral, 60 mg/m2, Once daily, 2 years or until unacceptable toxicity